Early results from LRF CLL4: A UK multicenter randomized trial by Catovsky, D, Richards, S, Hillmen, P

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial. by Hillmen, P, Richards, S, Catovsky, D, Grp, U

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial. by Catovsky, D, Else, M, Richards, S, Hillmen, P

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial. by Dearden, C, Richards, S, Else, M, Catovsky, D, Hillmen, P

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group) by Hillmen, P, Richards, S, Smith, A, Hamblin, T, Milligan, D, Catovsky, D

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Tria... by Catovsky, D, Richards, S, Dearden, C, Matutes, E, Dyer, M, Hillmen, P

UK experience of Ofatumumab in refractory B-CLL by Varghese, A, Pattinson, J, Carrington, P, Bloor, A, Follows, G, Hillmen, P, Schuh, A, Chowdhury, O

Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. by Chowdhury, O, Varghese, A, Pattinson, J, Carrington, P, Bloor, A, Follows, G, Hillmen, P, Schuh, A

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therap... by Rawstron, A, Kennedy, B, Evans, P, Davies, F, Richards, S, Haynes, A, Russell, N, Hale, G, Morgan, G, Jack, A, Hillmen, P

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. by Oscier, D, Dearden, C, Eren, E, Erem, E, Fegan, C, Follows, G, Hillmen, P, Illidge, T, Matutes, E, Milligan, D, Pettitt, A, Schuh, A, Wimperis, J

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. by Hale, G, Rebello, P, Brettman, L, Fegan, C, Kennedy, B, Kimby, E, Leach, M, Lundin, J, Mellstedt, H, Moreton, P, Rawstron, A, Waldmann, H, Osterborg, A, Hillmen, P

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL by Munir, T, Cohen, D, Milligan, D, Schuh, A, McParland, L, Chalmers, A, Varghese, A, Rawstron, A, Allsup, D, Marshall, S, Smith, A, Collett, C, Gregory, W, Duncombe, A, Hillmen, P

SAMHD1, A Putative Tumour Suppressor, Is Recurrently Mutated in Chronic Lymphocytic Leukaemia, and Is Associated with Poor Risk Features by Clifford, R, Ackroyd, S, Burns, A, Timbs, A, Maelfait, J, Dreau, H, Henderson, S, Ross, M, Bentley, D, Hillmen, P, Knight, S, Taylor, J, Hatton, C, Rehwinkel, J, Crow, Y, Schuh, A

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-... by Hillmen, P, Pettitt, A, Schuh, A, Milligan, D, Bowles, K, Bareford, D, Riaz, J, Follows, G, Rule, S, Wallis, J, Gribben, J, Noble, R, Pocock, C, Lisby, S, Carey, J, Gupta, I, Chang, C, McKeown, A

Clinical‐grade validation of whole genome sequencing reveals robust detection of low‐frequency variants and copy number alterations in CLL by Klintman, J, Barmpouti, K, Knight, S, Robbe, P, Dreau, H, Clifford, R, Ridout, K, Burns, A, Timbs, A, Bruce, D, Antoniou, P, Sosinsky, A, Becq, J, Bentley, D, Hillmen, P, Taylor, J, Caulfield, M, Schuh, A

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. by Catovsky, D, Richards, S, Matutes, E, Oscier, D, Dyer, M, Bezares, R, Pettitt, A, Hamblin, T, Milligan, D, Child, J, Hamilton, MS, Dearden, C, Smith, A, Bosanquet, A, Davis, Z, Brito-Babapulle, V, Else, M, Wade, R, Hillmen, P

Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL. by Osterborg, A, Dyer, M, Mayer, J, Hess, G, Hillmen, P, Schetelig, J, Schuh, A, Smolej, L, Beck, C, Dreyfus, B, Hellman, A, Kozlowski, P, Pfreundschuh, M, Rizzi, R, Spacek, M, Chan, G, Gupta, I, Phillips, J, Lisby, S, Wierda, W

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome by Roberts, C, Love, S, Eyre, T, Clifford, R, Boyle, L, Cabes, M, Schuh, A, Bloor, A, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, McCarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamopoulos, B, Weatherspoon, A

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome by Eyre, T, Clifford, R, Bloor, A, Boyle, L, Roberts, C, Cabes, M, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, Mccarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamatopoulos, B, Love, S, Wotherspoon, A, Schuh, A

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the... by Pettitt, A, Jackson, R, Carruthers, S, Dodd, J, Dodd, S, Oates, M, Johnson, G, Schuh, A, Matutes, E, Dearden, C, Catovsky, D, Radford, J, Bloor, A, Follows, G, Devereux, S, Kruger, A, Blundell, J, Agrawal, S, Allsup, D, Proctor, S, Heartin, E, Oscier, D, Hamblin, T, Rawstron, A, Hillmen, P